MetaVia is a clinical-stage biotechnology company positioned at the forefront of transforming treatments for cardiometabolic diseases. The company's compelling focus is on progressing therapeutic candidates to address critical healthcare needs in obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
The company's leading candidate, DA-1726, is an innovative dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). This novel approach holds significant promise in advancing obesity treatment strategies. Further reinforcing its domain expertise, MetaVia is developing vanoglipel (DA-1241), a pioneering G-Protein-Coupled Receptor 119 (GPR119) agonist, to address the unmet needs in treating MASH.
With a lack of details on founding year and past investments, MetaVia remains a potent investment opportunity for those looking to support groundbreaking advancements in biotechnology targeting widespread metabolic diseases.
